PUBLIC COMPANY
saveZEALAND PHARMA
USupdated 1mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
- phase3Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
- EP1A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity
- phase3Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
🐶 Hiring Signal
News
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzNovo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to…biospace · 4d ago
- Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsViking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more tha…biospace · 5d ago
- Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trialThe mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmo…biospace · 5d ago
- Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical dataRoche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fi…fiercebiotech · 1mo ago
- Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateCurrent leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…biospace · 1mo ago
- Roche commits to lean-mass preservation with Hanmi obesity dealFor $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.biopharma_dive · 1mo ago
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismRoche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.fiercebiotech · 1mo ago
- Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the na…fiercebiotech · 1mo ago
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 1mo ago
- Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100MThe terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.biospace · 1mo ago
comments(0)
5-min edit window · permanent after that